You are about to leave the Clinical Value website now.
In this interview, Prof Chiu discusses the value of NGS testing to identify lung cancer driver mutations to detect and treat lung cancer early. He also highlights the challenges in…
Read Article
The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care. Access the…
Read Article
This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as an example.
Read Article
This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations…
Read Article
Lung cancer is one of the most common forms of cancer, with 1.3 million people being diagnosed every year in APAC. Majority of these cases are diagnosed at late stages, when survival rates are low.
Our lung cancer education hub provide the latest insights to ensure the best chances of survival, disease understanding, diagnostic testing, genomic profiling and clinical decision support solutions are key to early diagnosis and personalized treatment. Multidisciplinary partnership and innovation can provide the opportunity to improve the lives of millions of people around the world.
This whitepaper shares recommendations on ensuring standardization and quality of NGS across the region, to realize the potential of NGS and establish more effective and market-appropriate…
READ MORE
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MORE
In this interview, Prof Chiu discusses the value of NGS testing to identify lung cancer driver mutations to detect and treat lung cancer early. He also…
READ MORE
In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.
READ MORE
NGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article,…
READ MORE
In this article, Dr Amit Rauthan shares insights on the challenges and opportunities for greater NGS adoption in India.
READ MORE
In this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly…
READ MORE
In this article, Dr David Tan discusses the potential of NGS in Singapore, where the adoption of this technology is only just beginning to take root.
READ MORE
In this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.
READ MORE
While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…
READ MORE
This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as…
READ MORE
This study proposes a unified framework to classify targets for precision cancer medicine based on clinical evidence of utility, to aid oncologists in prioritising potential targets…
READ MORE
The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular…
READ MOREThis whitepaper shares recommendations on ensuring standardization and quality of NGS across the region, to realize the potential of NGS and establish more effective and market-appropriate…
READ MORE
This guideline aims to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the…
READ MOREThe NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in…
READ MOREThis report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches…
READ MORE
These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
READ MOREDiagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MORE
Expert talks and panels on genomic profiling, liquid biopsy, and novel gene management in cancer across Asia-Pacific and global contexts.
READ MORE
Watch this webinar to get updates on advancements in lung cancer treatment, including resectable NSCLC, thoracic surgery, neoadjuvant immunotherapy.
READ MORE
Missed the satellite symposium session from ESMO 2023? Access the webcast recording here.
READ MORE
The field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place…
READ MORE
Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Join the…
READ MORE
To enable value-based healthcare, several important steps are needed. In this presentation and Q&A, Ingel Demedts discusses the project “Value-based care in lung cancer: a case…
READ MORE
The growing amount of clinical data available for each patient, clinicians need to manage massive genomic information, histological analysis tools, and clinical trials and publications. They…
READ MORE
Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Join the webinar to hear from…
READ MORE
Several EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. While tissue biopsy samples continue to be the…
READ MORE
Several EGFR Tyrosine Kinase Inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. A robust and approved Companion Diagnostic (CDx) assay…
READ MORE
Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. Join the webinar to hear from pulmonologist Dr James…
READ MORE
Comprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how…
READ MORE